Latest news with #EZZLifeScience
The Australian
25-07-2025
- Health
- The Australian
CMG enters mobility market as joint health interest accelerates
CMG launches UC-II, a collagen-based supplement for joint mobility Product targets knee pain and stiffness with low-dose, once-daily format Joint health market expanding alongside Australia's ageing population Special Report: Joint pain has become a major focus for Australia's booming complementary medicines industry, now worth more than $6.4 billion a year. As the population ages and demand for non-surgical mobility solutions grows, a number of ASX-listed companies are positioning for growth in the space. Among them are Vita Life Sciences (ASX:VLS), EZZ Life Science (ASX:EZZ), Star Combo Pharma (ASX:S66) and McPhersons (ASX:MCP). While each has its own strategy, the common thread is clear: consumers are spending more on supplements that promise functional outcomes like pain relief, energy support and healthy ageing. Now, Complementary Medicines Group (CMG) is entering the conversation with a new product focused on knees - the part of the body most often linked with mobility decline. Called UC-II, the once-daily capsule contains undenatured type II collagen and has been shown in clinical studies to support joint function, reduce stiffness and improve walking ability in people experiencing mild osteoarthritis or wear-and-tear from an active lifestyle. Dr Brad McEwen PhD, a researcher at CMG, said the formula offered something new for consumers. 'UC-II works by helping the immune system recognise inflammation in the joint and respond appropriately. It targets the underlying cause, not just the symptoms,' he said. 'What makes it unique is the dose. You only need 40 milligrams per day. It is an efficient, well-tolerated alternative to high-dose glucosamine or chondroitin.' Market conditions are shifting Mobility health has emerged as one of the most promising supplement categories in Australia, particularly among people aged 35 and over. More than half of Australian adults use complementary medicines and nearly three in four households report keeping supplements on hand. Pill fatigue, rising interest in preventive health and a growing appetite for clinically validated products are all shaping how consumers choose what to buy. CMG's UC-II has been formulated to address those trends, with supporting evidence from more than a dozen clinical trials. In a six-month study, participants taking UC-II reported improved joint flexibility and reduced pain when climbing stairs, standing upright and walking longer distances. The product is now available through Go Vita stores nationally and is sold under several trusted brand names. Quality and compliance remain key Australia is considered one of the most tightly regulated markets in the world for complementary medicines. All products must be listed on the Australian Register of Therapeutic Goods and adhere to standards set by the Therapeutic Goods Administration. That quality assurance is also a key reason why exports have climbed to more than $1.2 billion per year. For CMG, the goal is not just to enter the category, but to lead with a formulation that is simple, proven and well-positioned for both domestic and export markets. With continued growth in the broader sector and increasing interest in mobility-focused products, the company is hoping UC-II will meet a real and growing need. This article was developed in collaboration with Complementary Medicines Group, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
The Australian
10-07-2025
- Business
- The Australian
EZZ, University of Sydney test bone supplement
EZZ inks research services deal with University of Sydney for study on effects of a supplement on bone growth Two-year project will assess an EZZ proprietary formulation and is expected to conclude in March 2027 Project reflects EZZ's commitment to advance life science through research with academic institutions Special Report: Life science company EZZ Life Science has joined forces with the University of Sydney in a cutting-edge research project to investigate the effects of a novel multi-ingredient supplement on bone growth. The research services agreement marks a key step in the strategy of EZZ Life Science Holdings (ASX: EZZ) to develop scientifically backed health products, with the study set to explore how a unique blend of nutrients could support stronger, healthier bones. Under the collaboration – to be led by Associate Professor Zufu Lu and Professor Hala Zreiqat of the School of Biomedical Engineering – in vitro research will examine effects of a novel multi-ingredient nutritional supplement on bone growth. The two-year project will assess a proprietary formulation containing lysine, calcium carbonate, vitamin D3, vitamin B2, zinc gluconate, taurine, glutamine, glycine and magnesium. The research will evaluate the formulation's potential to support bone health using advanced cellular and molecular models. Scientifically validated health and wellness products The project with the University of Sydney reflects EZZ's broader commitment to advance life science through credible, high-impact research with academic institutions. Through these collaborations and focused research areas, EZZ continues to expand its range of health and wellness products, aiming to provide scientifically validated solutions to consumers globally. Under the agreement, the university will provide annual progress reports and a final report upon completion of the research, which is expected to conclude by March 2027. 'Important step in our strategy' EZZ's Non-Executive Chair Glenn Cross said the company was excited to work with the University of Sydney on the important research initiative. 'Their world-class biomedical research capabilities and rigorous scientific standards make them an ideal institution to help evaluate and validate our formulation,' he said. 'This study represents an important step in our strategy to invest in evidence-based innovation and drive the development of products that support long-term health outcomes." This article was developed in collaboration with EZZ Life Science Holdings, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Yahoo
09-07-2025
- Business
- Yahoo
Discover 3 ASX Penny Stocks With Market Caps Under A$3B
As Australian shares anticipate a modest gain amid the Reserve Bank's unexpected decision to hold rates, investors are navigating a complex landscape influenced by global trade tensions and fluctuating commodity prices. In this context, penny stocks—though an outdated term—remain relevant for those seeking opportunities in smaller or emerging companies. By focusing on financial health and growth potential, these stocks can offer both stability and upside, making them an intriguing option for investors looking to explore promising avenues within the market. Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.365 A$104.6M ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$2.43 A$114.63M ★★★★★★ GTN (ASX:GTN) A$0.63 A$120.15M ★★★★★★ IVE Group (ASX:IGL) A$2.93 A$451.75M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.70 A$449.5M ★★★★★★ Sugar Terminals (NSX:SUG) A$0.99 A$360M ★★★★★★ Navigator Global Investments (ASX:NGI) A$1.73 A$847.84M ★★★★★☆ Accent Group (ASX:AX1) A$1.485 A$892.76M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.99 A$189.33M ★★★★★★ CTI Logistics (ASX:CLX) A$1.79 A$144.17M ★★★★☆☆ Click here to see the full list of 468 stocks from our ASX Penny Stocks screener. Let's dive into some prime choices out of the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Djerriwarrh Investments Limited is a publicly owned investment manager with a market cap of A$825.98 million. Operations: The company's revenue is primarily derived from its portfolio of investments, amounting to A$50.84 million. Market Cap: A$825.98M Djerriwarrh Investments demonstrates financial stability with short-term assets of A$53.2 million covering both short and long-term liabilities, while its debt is well covered by operating cash flow. The company's earnings have grown significantly, outpacing the broader Capital Markets industry over the past year. Despite a low Return on Equity of 5.4%, Djerriwarrh's interest payments are well covered by EBIT at 21.1 times coverage, indicating strong financial management. However, its dividend yield of 4.86% isn't fully supported by free cash flows, suggesting potential sustainability concerns in this area despite overall positive earnings growth trends and reduced debt levels over time. Take a closer look at Djerriwarrh Investments' potential here in our financial health report. Explore historical data to track Djerriwarrh Investments' performance over time in our past results report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Kingsgate Consolidated Limited is involved in the exploration, development, and mining of gold and silver mineral properties with a market capitalization of A$647.92 million. Operations: The company's revenue is primarily generated from its Chatree segment, amounting to A$210.69 million. Market Cap: A$647.92M Kingsgate Consolidated Limited's financial profile highlights its robust earnings growth, with a remarkable 1203% increase over the past year, surpassing industry averages. The company's Return on Equity stands at an outstanding 74.4%, while its net debt to equity ratio is satisfactory at 17.9%. Despite high non-cash earnings and short-term assets exceeding short-term liabilities, long-term liabilities remain uncovered by current assets. Recent announcements of a share buyback program reflect strategic capital management aimed at enhancing shareholder value. Trading significantly below estimated fair value, Kingsgate presents potential opportunities within the penny stock segment in Australia's mining sector. Click here and access our complete financial health analysis report to understand the dynamics of Kingsgate Consolidated. Examine Kingsgate Consolidated's earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: MFF Capital Investments Limited is an investment firm manager with a market cap of A$2.61 billion. Operations: The company generates revenue primarily through its equity investment segment, amounting to A$1.01 billion. Market Cap: A$2.61B MFF Capital Investments demonstrates strong financial health, with cash exceeding total debt and short-term assets of A$3.0 billion covering both short-term and long-term liabilities. The company boasts high-quality earnings, a robust Return on Equity of 28.2%, and impressive earnings growth of 51.9% over the past year, outpacing industry averages. MFF's stable weekly volatility at 3% indicates consistent performance while maintaining shareholder value without significant dilution. Trading at a discount to fair value, it offers an attractive dividend yield of 3.6%. Its experienced board further supports strategic decision-making in the capital markets sector. Unlock comprehensive insights into our analysis of MFF Capital Investments stock in this financial health report. Review our historical performance report to gain insights into MFF Capital Investments' track record. Embark on your investment journey to our 468 ASX Penny Stocks selection here. Contemplating Other Strategies? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:DJW ASX:KCN and ASX:MFF. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-07-2025
- Business
- Yahoo
Kogan.com And Two Other ASX Penny Stocks To Watch
The Australian market is poised for a slight retreat, with traders eyeing potential impacts from international tariff tensions and awaiting the Reserve Bank's decision on interest rates. Amidst these broader economic shifts, investors often seek opportunities in lesser-known sectors that could offer unique growth prospects. Penny stocks, though considered niche today, remain relevant as they represent smaller or newer companies that may provide significant returns when supported by strong financials. In this context, we explore three promising penny stocks on the ASX worth watching for their balance sheet strength and potential long-term success. Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.365 A$104.6M ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$2.40 A$113.22M ★★★★★★ GTN (ASX:GTN) A$0.64 A$122.06M ★★★★★★ IVE Group (ASX:IGL) A$2.92 A$450.21M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.70 A$449.5M ★★★★★★ Sugar Terminals (NSX:SUG) A$0.99 A$363.6M ★★★★★★ Navigator Global Investments (ASX:NGI) A$1.73 A$847.84M ★★★★★☆ Accent Group (ASX:AX1) A$1.49 A$895.77M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$4.03 A$191.22M ★★★★★★ CTI Logistics (ASX:CLX) A$1.80 A$144.98M ★★★★☆☆ Click here to see the full list of 469 stocks from our ASX Penny Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Ltd is an online retailer based in Australia, with a market capitalization of A$388.32 million. Operations: Ltd generates revenue through its operations in Australia, with A$309.36 million from Kogan Parent and A$9.96 million from Mighty Ape, and in New Zealand, with A$40.02 million from Kogan Parent and A$124.88 million from Mighty Ape. Market Cap: A$388.32M Ltd, with a market capitalization of A$388.32 million, is trading significantly below its estimated fair value. Despite negative earnings growth of 73.9% over the past year and declining profits over five years, the company remains debt-free with sufficient short-term assets to cover both short and long-term liabilities. Recent executive changes include appointing Belinda Cleminson as Company Secretary. The company extended its buyback plan duration until May 2026, indicating confidence in future performance despite current challenges such as low profit margins and a dividend not well covered by earnings. Earnings are forecasted to grow annually by 34.52%. Jump into the full analysis health report here for a deeper understanding of Review our growth performance report to gain insights into future. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Platinum Investment Management Limited is a publicly owned hedge fund sponsor with a market cap of A$278.22 million. Operations: The company generates revenue primarily from Funds Management, contributing A$157.13 million, with an additional A$4.63 million from Investments and Other activities. Market Cap: A$278.22M Platinum Investment Management Limited, with a market cap of A$278.22 million, is trading at 32.6% below its fair value estimate, suggesting potential undervaluation. The company remains debt-free and has robust short-term assets (A$169.7M) exceeding liabilities, yet faces challenges with declining earnings and lower profit margins compared to last year. Despite high-quality earnings and stable volatility, the dividend yield of 6% isn't well covered by current earnings. The management team is experienced; however, the board's average tenure suggests inexperience. Recent M&A discussions may impact future strategic direction amidst forecasted earnings decline of 10.4% annually over three years. Click to explore a detailed breakdown of our findings in Platinum Investment Management's financial health report. Learn about Platinum Investment Management's future growth trajectory here. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Sheffield Resources Limited focuses on the evaluation and development of mineral sands in Australia, with a market cap of A$78.96 million. Operations: Sheffield Resources Limited has not reported any specific revenue segments. Market Cap: A$78.96M Sheffield Resources Limited, with a market cap of A$78.96 million, is pre-revenue and unprofitable, experiencing increasing losses over the past five years. Despite this, it has no debt and a solid cash runway exceeding three years if free cash flow growth continues at historical rates. The company's short-term assets (A$8.4M) comfortably cover its short-term liabilities (A$310K), indicating sound liquidity management. Its board of directors is considered experienced with an average tenure of 5.1 years, although there's insufficient data on management experience. Earnings are forecast to grow significantly at 79.69% annually despite current challenges. Take a closer look at Sheffield Resources' potential here in our financial health report. Gain insights into Sheffield Resources' outlook and expected performance with our report on the company's earnings estimates. Embark on your investment journey to our 469 ASX Penny Stocks selection here. Interested In Other Possibilities? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:KGN ASX:PTM and ASX:SFX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
07-07-2025
- Business
- Yahoo
ASX Penny Stock Highlights: Ai-Media Technologies And Two Other Noteworthy Picks
As the ASX 200 started the new financial year trading flat, with sectors like Utilities and IT showing positive intra-day gains, investors are closely watching for opportunities amid mixed performances across various industries. Penny stocks, although an older market term, continue to represent smaller or less-established companies that may present value and growth potential. By focusing on those with solid financials and a clear path forward, investors can uncover promising opportunities in these under-the-radar stocks. Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.375 A$107.47M ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$2.46 A$116.05M ★★★★★★ GTN (ASX:GTN) A$0.63 A$120.15M ★★★★★★ IVE Group (ASX:IGL) A$2.85 A$439.42M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.785 A$471.97M ★★★★★★ Tasmea (ASX:TEA) A$3.66 A$862.38M ★★★★★☆ Navigator Global Investments (ASX:NGI) A$1.695 A$830.68M ★★★★★☆ Lindsay Australia (ASX:LAU) A$0.74 A$234.75M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.54 A$167.97M ★★★★★★ CTI Logistics (ASX:CLX) A$1.755 A$141.36M ★★★★☆☆ Click here to see the full list of 477 stocks from our ASX Penny Stocks screener. Let's dive into some prime choices out of the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Ai-Media Technologies Limited offers technology-driven captioning, transcription, and translation services across Australia, New Zealand, Singapore, Malaysia, North America, and the United Kingdom with a market cap of A$116.94 million. Operations: The company's revenue is derived from its Internet Software & Services segment, amounting to A$65.30 million. Market Cap: A$116.94M Ai-Media Technologies Limited, with a market cap of A$116.94 million and revenue of A$65.30 million, is leveraging its LEXI platform to expand accessibility in multilingual broadcasting. Recent partnerships with Lightning International and AudioShake enhance its real-time translation capabilities, opening new revenue streams by breaking language barriers across global markets. While currently unprofitable, Ai-Media has improved its financial position over the past five years and maintains a sufficient cash runway for more than three years due to positive free cash flow growth. Despite these strengths, the company faces challenges such as an inexperienced board and ongoing unprofitability. Take a closer look at Ai-Media Technologies' potential here in our financial health report. Review our growth performance report to gain insights into Ai-Media Technologies' future. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Helloworld Travel Limited is a travel distribution company operating in Australia, New Zealand, and internationally with a market cap of A$243.36 million. Operations: The company's revenue is primarily generated from its Travel Operations in Australia (A$153.71 million), New Zealand (A$36.06 million), and the Rest of the World (A$3.72 million), along with contributions from its Transport, Logistics and Warehousing segment (A$15.20 million). Market Cap: A$243.36M Helloworld Travel Limited, with a market cap of A$243.36 million, is strategically positioned in the travel industry but faces challenges such as declining net profit margins and negative earnings growth over the past year. Despite this, it remains debt-free and offers a dividend yield of 7.38%, though not fully covered by free cash flows. Recent M&A activity suggests potential consolidation with Webjet Group, which could enhance its online booking capabilities if pursued successfully. The company trades at a favorable price-to-earnings ratio of 9.3x compared to the broader Australian market and has shown stable weekly volatility over the past year. Dive into the specifics of Helloworld Travel here with our thorough balance sheet health report. Gain insights into Helloworld Travel's outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: SciDev Limited offers environmental solutions for water-intensive industries across Australia, the United States, Asia, and other international markets, with a market cap of A$68.43 million. Operations: The company's revenue is primarily derived from its Chemical Services segment, which generated A$85.79 million, followed by the Water Technology segment with A$23.04 million. Market Cap: A$68.43M SciDev Limited, with a market cap of A$68.43 million, is trading at 51% below its estimated fair value, indicating potential undervaluation in the penny stock segment. The company has transitioned to profitability over the past year and forecasts suggest earnings growth of 45.4% annually. SciDev's financial health appears robust with short-term assets covering both short and long-term liabilities, while its interest payments are well covered by EBIT at 7.2x coverage. However, despite having more cash than total debt and stable weekly volatility (10%), the company's Return on Equity remains low at 4%. Navigate through the intricacies of SciDev with our comprehensive balance sheet health report here. Assess SciDev's future earnings estimates with our detailed growth reports. Click this link to deep-dive into the 477 companies within our ASX Penny Stocks screener. Ready For A Different Approach? This technology could replace computers: discover the 27 stocks are working to make quantum computing a reality. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:AIM ASX:HLO and ASX:SDV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
